India pharma Outlook Team | Tuesday, 16 June 2026
In a major regulatory move aimed at strengthening drug safety and curbing misuse, the Centre has made it mandatory for consumers to present a valid doctor’s prescription to purchase cough syrups and other syrup-based medicines. The decision has been implemented through the Drugs (Fifth Amendment) Rules, 2026, which remove syrups from the list of medicines that previously enjoyed certain exemptions under the Drugs Rules, 1945.
The amendment effectively ends the over-the-counter (OTC) sale of syrup-based medicines across the country, bringing them under stricter regulatory oversight. Consumers will now need a prescription from a registered medical practitioner before purchasing such products.
The latest policy change follows growing concerns over the misuse of cough syrups and the need for tighter monitoring of liquid medicinal products. Health authorities believe that requiring medical prescriptions will promote responsible usage while reducing the risks associated with self-medication and inappropriate consumption.
The government’s decision is also part of broader efforts to enhance pharmaceutical safety standards following a series of incidents involving contaminated cough syrups that triggered concerns both in India and overseas. Regulatory scrutiny of the sector has increased significantly in recent years, leading to multiple reforms aimed at improving quality control and patient safety.
Previously, certain cough syrups were included under Schedule K exemptions, allowing them to be sold through limited-license retail outlets in smaller towns and villages where access to pharmacies was restricted. With the latest amendment, cough syrups will now be dispensed only through duly licensed pharmacies in accordance with the Drugs and Cosmetics Act.
The revised framework is expected to bring greater uniformity in medicine distribution practices across urban and rural markets while ensuring that consumers receive appropriate medical guidance before using syrup-based medications.
Also Read: Centre Issues Heat Advisory, Recommends AYUSH Remedies
The new prescription-only requirement is likely to impact pharmacies, retailers, distributors, and pharmaceutical manufacturers, particularly companies with significant exposure to cough and cold medication segments. However, healthcare experts have largely welcomed the move, stating that tighter controls could improve patient outcomes and reduce the risks associated with misuse or substandard products.
Industry stakeholders are now expected to align their distribution and compliance practices with the revised regulations as the government continues to strengthen oversight of the pharmaceutical sector and prioritize patient safety.
.jpg)
